New drugs for treatment of multiple myeloma.

Benedetto Bruno, Marcello Rotta, Luisa Giaccone, Massimo Massaia, Alessandra Bertola, Antonio Palumbo, Mario Boccadoro

Journal: The Lancet. Oncology 2004;5(7):430-42

PMID: 15231250

Full Text on Elsevier Science View on PubMed

Abstract

Multiple myeloma (MM) is a disease of plasma cells that has fatal consequences. New insights into the biology of MM have identified molecular mechanisms that hold promise as therapeutic targets. Laboratory and preclinical studies have shown that intracellular regulatory proteins and functional interactions between MM cells and the bone-marrow microenvironment have a pivotal role in the growth, survival, drug resistance, and malignant progression of MM cells. New agents associated with molecular targets have prompted clinical investigators to design new treatment strategies initially for advanced MM and later for newly diagnosed MM, with encouraging preliminary results. Here, we discuss the mechanisms of action of these new rational drugs and the preliminary clinical outcomes of a new treatment regimen for MM.

Address: Division of Haematology, University of Turin, Department of Medicine and Experimental Oncology, Laboratory of Haematology and Oncology, Centro di Ricerca in Medicina Sperimentale, Ospedale San Giovanni Battista, Italy. [email protected]

DOI: 10.1016/S1470-2045(04)01511-6

Link outs

Free resources

Medical:

https://medlineplus.gov/multiplemyeloma.html

Other Literature Sources:

https://www.lens.org/lens/search/patent/list?q=ref...

Subscription / membership required

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S1470...

MeSH Terms: 2-Methoxyestradiol, Angiogenesis Inhibitors, Antineoplastic Agents, Apoptosis, Arsenic Trioxide, Arsenicals, Clinical Trials as Topic, Diphosphonates, Enzyme Inhibitors, Estradiol, Humans, Multiple Myeloma, Neovascularization, Pathologic, Oxides, Receptors, Vascular Endothelial Growth Factor, Signal Transduction, Thalidomide